Mobia Medical, Inc. · NASDAQ:MOBI
Mobia Medical — Q2 2026 Earnings Presentation
24 slides from Mobia Medical's earnings presentation, Aug 11, 2026
Slide 1: Mobia Medical Investor Presentation
Mobia Medical Investor Presentation June 2026
Slide 2: Disclaimer: Forward-Looking Statements
DISCLAIMER Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this presentation that do not relate to matters of hist
Slide 3: Redefining Stroke Recovery with Vivistim Therapy
Redefining Stroke Recovery with Vivistim® Therapy Stroke is a leading cause of long-term disability in the U.S. Even with sophisticated acute intervention, a significant number of survivors will suffer from life-altering impairments1 First-and-only clinically-validated, FDA-approved solution for sur
Slide 4: Vivistim System is the First and Only FDA-Approved Intervention for Chronic Stroke Recovery
Vivistim® System is the First and Vivistim® Paired VNS Therapy Only FDA-Approved Intervention Increases Neuroplasticity to for Chronic Stroke Recovery Restore Hand and Arm Function 4
Slide 5: Overview of Stroke
Overview of Stroke Ischemic Stroke Hemorrhagic Stroke (Clots) (Bleeds) Occurs when a vessel Occurs when a weakened supplying blood to the brain vessel ruptures and bleeds is obstructed into surrounding brain 87% of all Strokes in U.S. are Ischemic1 [1] Graphics and data from American Heart Associati
Slide 6: Treatment of Stroke Historically Focused on Survival and Stabilization
Treatment of Stroke Historically Focused on Survival and Stabilization ~800K Annual Stroke Incidence1 ~9M Ischemic Stroke Survivors1 Acute Phase Chronic Phase Significant reduction in stroke mortality since 20002,3 means more patients survive with life-altering impairment [1] Martin, Seth S., et al.
Slide 7: Recovery Plateaus and Established Care Pathways End After the First 3-6 months
Recovery Plateaus and Established Care Pathways End After the First 3-6 months Acute Stroke Functional plateau occurs at 3-6 months Recovery Recovery of Motor Plateau Function Acute Sub-Acute Chronic Phase Phase Phase DAYS WEEKS 3 MONTHS 6 MONTHS+ Vivistim® Therapy is proven to deliver significant f
Slide 8: Vivistim Therapy Enhances Neuroplasticity to Remodel Motor Pathways in the Brain
Vivistim® Therapy Enhances Neuroplasticity to Remodel Motor Pathways in the Brain Vivistim® Paired VNS Therapy New Neural Pathways Increased Task Specific Practice Surrounding neurons take over Neuromodulators during occupational or physical function lost by damaged ones generated by VNS put the bra
Slide 9: Vivistim Therapy Drove 2-3x Greater Recovery in Pivotal Trial
Vivistim® Therapy Drove 2-3x Greater Recovery in Pivotal Trial Significant Improvements in Hand & Arm Function1 Randomized, sham controlled, triple Blinded Phase (Active vs. Control) Cross-over Phase (Control) + + blinded, n=108 7 * 6 * 5 Control group received intensive rehab 4 2-3x with sham stimu
Slide 10: Extensive Body of Clinical Evidence with >20 Publications on Vivistim Therapy
Extensive Body of Clinical Evidence with >20 Publications on Vivistim® Therapy Real-world evidence to further support coverage GRASP Registry development and clinical guidelines ongoing Proven efficacy in large RCT of n=108 patients with up to 1-year follow up Pivotal RCT 1,2 Feasibility, safety, an
Slide 11: Real-World Patient Outcomes Demonstrate Transformative Impact of Vivistim Therapy
Real-World Patient Outcomes Demonstrate Transformative Impact of Vivistim® Therapy Baseline Vivistim® Therapy Day 1 2 weeks 5 weeks 8 weeks Kathy 69 years old, 3 years post-stroke, with her handwriting examples1 [1] Represents data from one patient presented for illustrative purposes. Although we be
Slide 12: Real-World Patient Outcomes Demonstrate Transformative Impact of Vivistim Therapy
Real-World Patient Outcomes Demonstrate Transformative Impact of Vivistim® Therapy Donna regained the ability to David regained the ability Christa regained the ability prepare meals and fold to drive a car to contribute to household laundry activities +6 on FMA-UE +6 on FMA-UE +12 on FMA-UE These F
Slide 13: Vivistim Therapy Addresses Significant Stroke Survivor Population
Vivistim® Therapy Addresses Significant Stroke Survivor Population Estimated Prevalence Estimated Annual Incidence ~10M ~800K Total Stroke Population1 Stroke Survivors Strokes per year in the U.S. in the U.S. ~400K Ischemic Stroke Survivors1,2 ~9M Per Year Total On-label for Vivistim® Therapy ~200K
Slide 14: Building and Scaling Our Market
Building and Scaling Our Market What it takes to BUILD the market What it takes to SCALE the market Empower HCP champions to drive adoption Increase reach across the US Target stroke hospital decision-makers to establish new Expand geographic footprint and add sites to care pathways support scale Ed
Slide 15: Field-Based Commercial Team Activates Accounts and Deepens Engagement
Field-Based Commercial Team Activates Accounts and Deepens Engagement Current Territory Coverage1 Direct Sales Force Model Therapy Development Territory Managers (TMs) Specialists (TDSs) Activating Vivistim® Therapy Building network of therapy sites programs at stroke centers Engaging therapists and
Slide 16: Target Accounts for Vivistim Therapy Programs
Target Accounts for Vivistim® Therapy Programs Primary and • ~1,500 stroke centers in U.S.1 Comprehensive • ~70% of all acute strokes are seen Stroke Centers at 900 hospitals in U.S.2 • Targeting specialists in upper Neuro-Specialized extremity neuro recovery, with Therapy Sites stroke-centered prac
Slide 17: Vivistim Therapy Journey
Vivistim® Therapy Journey STROKE EVENT ENGAGEMENT 3+ MONTHS • Physician Referrals • Acute Care for Ischemic Stroke 1 2 • Hospital Discharge • Therapist Referrals • Sub-Acute PT & OT • Direct Patient Engagement IN-CLINIC VIVISTIM® THERAPY ASSESSMENT CONSULT IMPLANT VIVISTIM® THERAPY FOR LIFE 3 4 5 6
Slide 18: Established Coding and CMS Payment in Place, Focus Shifts to Expanding Commercial Coverage
Established Coding and CMS Payment in Place, Focus Shifts to Expanding Commercial Coverage Category I CPT code 64568 – long established New Tech APC 1580 code ~$45k Medicare Reimbursement1 in 2026 Re-assessed annually by Medicare Medicare coverage when medically necessary, no prior authorization
Slide 19: Defining the Category with First-of-its-Kind Therapy and Durable Competitive Moat
Defining the Category with First-of-its-Kind Therapy and Durable Competitive Moat Alternative Approaches ✓ Robust clinical evidence with randomized data demonstrating efficacy and durability Existing Technologies Assistive orthoses Minimally invasive procedure with well-known ✓ ease and safety profi
Slide 20: Our Long-Range Vision
Our Long-Range Vision Build a New Market Establish Standard of Care and Expand to New Markets in Chronic Stroke Expand Access and More Patients Today Tomorrow Future • Continue to expand our market development • Publish GRASP Registry real-world data to • Pursue label for additional efforts to broad
Slide 21: Strong and Sustainable Revenue Growth with Attractive Gross Margins
Strong and Sustainable Revenue Growth with Attractive Gross Margins 113% growth in Q1 ‘26 vs. Q1 ’25 $12.1M $10.7M $9.0M $6.7M $5.7M $4.0M $4.1M $4.4M $3.1M 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4 2026 Q1 Full Year Revenue $15.6M $32.0M Gross Margin 79.6% 81.1% 82.3% Note: qu
Slide 22: Appendix
Appendix 22
Slide 23: The Vivistim System
The Vivistim® System Surgical Components Non-Surgical Components Stroke application & programming 4 software (SAPS) 1 Implantable lead Magnet 5 for at-home stimulation activation by patient Implantable pulse 2 generator (IPG) Remote 6 for in-clinic stimulation activation by therapist 3 Tunneling Too
Slide 24: Key Clinical Publications on Vivistim Paired VNS Therapy
Key Clinical Publications on Vivistim® Paired VNS Therapy Pivotal Study Results 1. Dawson J, Liu CY, Francisco GE, et al. (April 2021). “Vagus Nerve Stimulation Paired with Rehabilitation for Upper Limb Motor Function after Ischaemic Stroke (VNS- REHAB): A Randomised, Pivotal, Device trial.” Lancet,